OmniAb (OABI) to Release Earnings on Thursday

OmniAb (NASDAQ:OABI - Get Free Report) is expected to post its Q1 2025 quarterly earnings results after the market closes on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $4.49 million for the quarter.

OmniAb (NASDAQ:OABI - Get Free Report) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. OmniAb had a negative net margin of 308.78% and a negative return on equity of 20.97%. The company had revenue of $10.80 million for the quarter, compared to analysts' expectations of $10.13 million. During the same quarter in the prior year, the firm earned ($0.14) EPS. On average, analysts expect OmniAb to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OmniAb Trading Down 3.7 %

OmniAb stock traded down $0.07 during midday trading on Monday, reaching $1.69. The stock had a trading volume of 355,594 shares, compared to its average volume of 609,759. The company has a fifty day moving average price of $2.43 and a two-hundred day moving average price of $3.28. The company has a market capitalization of $205.80 million, a P/E ratio of -2.69 and a beta of 0.06. OmniAb has a 12 month low of $1.64 and a 12 month high of $4.96.

Insider Buying and Selling

In other OmniAb news, Director John L. Higgins acquired 125,750 shares of the company's stock in a transaction on Thursday, March 20th. The shares were acquired at an average cost of $2.35 per share, with a total value of $295,512.50. Following the completion of the acquisition, the director now directly owns 2,762,887 shares in the company, valued at $6,492,784.45. This trade represents a 4.77 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Matthew W. Foehr sold 13,964 shares of OmniAb stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.68, for a total transaction of $51,387.52. Following the completion of the transaction, the chief executive officer now owns 3,798,682 shares of the company's stock, valued at $13,979,149.76. The trade was a 0.37 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 67,985 shares of company stock valued at $189,773. 8.60% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Royal Bank of Canada lowered their target price on OmniAb from $7.00 to $4.00 and set an "outperform" rating on the stock in a research report on Thursday, March 27th. Benchmark dropped their price objective on shares of OmniAb from $8.00 to $6.00 and set a "buy" rating on the stock in a research note on Thursday, March 20th. Finally, HC Wainwright restated a "buy" rating and issued a $11.00 target price on shares of OmniAb in a report on Wednesday, March 19th.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.